Efbemalenograstim alfa for the primary/secondary prophylaxis of intermediate-risk febrile neutropenia (FN) chemotherapy regimen with risk factors in patients with non-small cell lung cancer (NSCLC): A randomized, multicenter, exploratory clinical trial.

Authors: Mengjie Li, Dingzhi Huang, Tianhui Gao, Caixia Liu, Haitao Lan, Jun Ge, Wei Zheng, Xiaoyong Tang, Chuangzhou Rao

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20560

Source: Full article

e20560